Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

PURPOSE: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Laidlaw, Tanya M, Menzies-Gow, Andrew, Caveney, Scott, Han, Joseph K, Martin, Nicole, Israel, Elliot, Lee, Jason K, Llanos, Jean-Pierre, Martin, Neil, Megally, Ayman, Parikh, Bhavini, Vong, Sylvia, Welte, Tobias, Corren, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488831/
https://www.ncbi.nlm.nih.gov/pubmed/37692126
http://dx.doi.org/10.2147/JAA.S413064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488831/
https://www.ncbi.nlm.nih.gov/pubmed/37692126
http://dx.doi.org/10.2147/JAA.S413064

Ejemplares similares